Exciting advancements in the field of mantle cell lymphoma
John P. Leonard, M.D., professor of medicine, spoke to OncLive about some of the exciting advancements taking place in the field of mantle cell lymphoma (MCL).
In the MCL landscape, the BTK inhibitor ibrutinib (Imbruvica) has made a big difference for patients in improving their outcomes, Leonard explains.
Additionally, researchers are learning more about sub-classifying the MCL population, and the future is going to involve more combinations with ibrutinib. These include regimens with venetoclax (Venclexta), cell cycle inhibitors, or other novel compounds to try to minimize or treat resistance as well as extend the duration of remissions, he adds.